Moleculera Labs Inc., an Oklahoma City-based developer of tests for autoimmune neurologic conditions in children and adults, raised $1.06m in funding.
The round was led by i2E Inc. (which committed $530k through its Accelerate Oklahoma! Fund) with participation from SeedStep Angels ($225k) and other investors.
The company intends to use the funds to expand the development of its tests.
Led by Dr. Craig Shimasaki, co-founder and Chief Executive Officer, Moleculera Labs has developed a series of tests, the Cunningham Panel, which predicts a patient’s likelihood having Pediatric Autoimmune Neuropsychiatric Disorder Associated with Streptococci (PANDAS). PANDAS are treatable neurologic conditions that may be associated with motor tics and obsessive compulsive disorders (OCD), which are often associated with Autism Spectrum Disorders.